<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03855826</url>
  </required_header>
  <id_info>
    <org_study_id>NTFS01</org_study_id>
    <nct_id>NCT03855826</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy and Safety of Nifekalant Hydrochloride (NIF) Injection.</brief_title>
  <official_title>Evaluation of the Efficacy and Safety of Nifekalant Hydrochloride (NIF) Injection in the Treatment of Ventricular Tachycardia and Ventricular Fibrillation. A Multicenter, Randomized, Controlled, Open-label, Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sichuan Baili Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sichuan Baili Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy and safety evaluation of amiodarone and Nifekalant hydrochloride(NIF) for the
      treatment of ventricular tachycardia and ventricular fibrillation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After patients are hospitalized, they will be treated as usual in addition to antiarrhythmic
      drugs. DC will be performed again according to normal procedures for patients who were
      ineffective. Arrhythmia drugs can only be used with nifekalant or amiodarone at random.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2019</start_date>
  <completion_date type="Anticipated">January 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of efficacy</measure>
    <time_frame>24 hours after administration.</time_frame>
    <description>Efficacy of drugs in each group within 24 hours after administration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The efficiency rate without adjusting the drug dose</measure>
    <time_frame>24 hours after administration.</time_frame>
    <description>number of patients who no longer relapse after using the drug / total number of patients in the group × 100%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of electrical cardioversion used during the treatment</measure>
    <time_frame>24 hours after administration.</time_frame>
    <description>Number of electrical cardioversion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The success rate of DC in patients with first invalid cardioversion in the two groups</measure>
    <time_frame>24 hours after administration.</time_frame>
    <description>Number of patients ewith valid DC after the first invalid DC / Total number of patients with first invalid DC in this group × 100%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The average time from the start of administration to the last VT/VF no longer occurs</measure>
    <time_frame>24 hours after administration.</time_frame>
    <description>Patients who changed drugs will not be included statistics on this indicator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LVEF</measure>
    <time_frame>Before administration, and 24h to 72h after the start of administration.</time_frame>
    <description>Echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival rate</measure>
    <time_frame>30 days after administration.</time_frame>
    <description>Survival rate of the two groups of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ventricular tachycardia/ventricular fibrillation episodes</measure>
    <time_frame>Within 72 hours after drug administration.</time_frame>
    <description>Number of ventricular tachycardia/ventricular fibrillation episodes .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of patients who need to continue the intravenous research drug after 24 hours in the two groups</measure>
    <time_frame>24 hours after the start of the adminstration.</time_frame>
    <description>The number of patients who need to continue the intravenous research drug after 24 hours in the two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effective rate of the drug in each group within 72 hours after administration</measure>
    <time_frame>72 hours after administration.</time_frame>
    <description>The effective rate of the drug in each group within 72 hours after administration.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">756</enrollment>
  <condition>Ventricular Tachycardia</condition>
  <condition>Ventricular Fibrillation</condition>
  <arm_group>
    <arm_group_label>Nifekalant Hydrochloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nifekalant hydrochloride (50mg) should be dissolved into a 50ml dilution solution (0.9% sodium chloride injection or 5% glucose injection), and configured as 1mg/ml solution of nificaine hydrochloride. The dosage should be taken as needed. The diluted solution should be used within 24 hours. The amount of fluid per hour should not exceed 50ml when intravenously infused. It is recommended to use intravenous pump.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amiodarone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The concentration of more than 2 ampoule amiodarone injection in 500 ml (only isotonic grape solution) is suitable. Amiodarone should be administered as far as possible via the central venous route (administered separately).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nifekalant hydrochloride</intervention_name>
    <description>Both groups were given conventional treatment except for arrhythmia drugs.Only nyficarine hydrochloride or amiodarone hydrochloride could be used according to random results, and the antiarrhythmic drugs should be replaced according to the protocol rules.</description>
    <arm_group_label>Nifekalant Hydrochloride</arm_group_label>
    <other_name>Nifekalant Hydrochloride for Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amiodarone</intervention_name>
    <description>Both groups were given conventional treatment except for arrhythmia drugs.Only nyficarine hydrochloride or amiodarone hydrochloride could be used according to random results, and the antiarrhythmic drugs should be replaced according to the protocol rules.</description>
    <arm_group_label>Amiodarone</arm_group_label>
    <other_name>Amiodarone hydrochloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with persistent ventricular tachycardia or ventricular fibrillation who have
             a combined physical heart disease, or who have a conventional drug ineffective or
             persistent idiopathic ventricular tachycardia with amiodarone indications;

          -  Age ≥ 18 years old, gender is not limited.

        Exclusion Criteria:

          -  Patients with prolonged ventricular tachycardia with QT interval and patients with QTc
             interval of more than 500 ms before administration;

          -  Patients with torsades de pointes (Tdp);

          -  Patients with Brugada syndrome;

          -  Patients with severe atrioventricular block and without pacing protection;

          -  Patients with hypertrophic cardiomyopathy (HCM) with ventricular septal thickness or
             (and) left ventricular wall ≥ 15 mm;

          -  Pregnant or lactating women;

          -  Patients who are not suitable for the study, considered by investigators.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ling Ya Han</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shenyang Military Region General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jing Xiong</last_name>
    <phone>+86-028-85320612</phone>
    <email>xiongjing@bailipharm.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shenyang Military Region General Hospital</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 25, 2019</study_first_submitted>
  <study_first_submitted_qc>February 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2019</study_first_posted>
  <last_update_submitted>February 25, 2019</last_update_submitted>
  <last_update_submitted_qc>February 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
    <mesh_term>Ventricular Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amiodarone</mesh_term>
    <mesh_term>Nifekalant</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

